News and Announcements
CAVATAK Immunotherapy Combo shows more Anti-cancer Activity
- Published October 01, 2014 1:49PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX and Media Release, 30 September 2014
CAVATAK Immunotherapy Combination Demonstrates Superior Anti-cancer Activity Presented at the European society for medical oncology (ESMO) 2014 Congress
•Preclinical studies show CAVATAK combined with checkpoint inhibitor agents provides significantly greater anti-tumour activity than checkpoint inhibitors alone
•Data suggest an anti-tumour immune response
•Results strengthen CAVATAK ‘s potential role as combination therapy with checkpoint inhibitors, a major new class of anticancer immunotherapies
30 September 2014, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) overnight announced at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid that preclinical studies have generated further evidence of improved CAVATAK anti-cancer activity when used in combination with immune checkpoint inhibitors, a new class of cancer immunotherapies with blockbuster potential. CAVATAK is a proprietary formulation of a common cold virus that hass been shown to preferentially infect and attack cancer cells.
To view the full ASX and Media Release please click here.